Presentations on Exploring New Strategies in Adult Ph+ ALL - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations on Exploring New Strategies in Adult Ph+ ALL

Not a member of My prIME? Join now for instant access.

Discover new options for the treatment of adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) with downloadable slides presented at our ASH satellite symposium in Atlanta, Georgia. A variety of topics are discussed including the use of non-intensive versus aggressive initial therapy, how deep sequencing can influence treatment decisions, and the role for transplantation in the treatment of Ph+ ALL.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 11, 2017

Expiration Date

Dec 11, 2018

Featured Expert

  • Hagop M. Kantarjian, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Making it personal from the start: Initial assessment in adult Ph+ ALL

Featured Expert

  • Giovanni Martinelli, MD, PhD, University of Bologna, Bologna, Italy

Featured Topic

Is less best? Examining non-intensive initial therapy in Ph+ ALL

Featured Expert

  • Elias Jabbour, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Hit me with your best shot: The case for aggressive initial therapy in Ph+ ALL

Featured Expert

  • Sergio Giralt, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Is transplantation still needed in Ph+ ALL?

Featured Expert

  • Hugues de Lavallade, MD, PhD, King’s College Hospital , NHS Foundation Trust, London, United Kingdom

Featured Topic

How low can we go? The rationale for deep sequencing in preventing relapses in Ph+ ALL

Featured Expert

  • Hagop M. Kantarjian, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

prIME PointsTM

This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with ALL.

After successful completion of this educational activity, participants should be able to:

  • Identify risk factors for relapse in Ph+ ALL, including cytogenetic abnormalities and failure to achieve complete molecular remission
  • Select an appropriate therapeutic approach for Ph+ ALL, taking into consideration patient fitness, diagnostic findings, and factors related to hematopoietic stem cell transplantation
  • Interpret findings from contemporary techniques like qRT-PCR and deep sequencing to better predict outcomes and adjust therapy for patients with Ph+ ALL

This educational activity is supported by a grant from Takeda Oncology.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Giralt has disclosed that he has received consulting fees from Amgen, Celgene, Kite Pharma, Jazz, Novartis, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Jabbour has disclosed that he has received fees for contracted research from Amgen, Novartis, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kantarjian has disclosed that he has received consulting fees from Abbvie, Actinium, Amgen, ARIAD, Bristol-Myers Squibb, Immunogen, Orsinex, and Pfizer. He also received research grants to his institution from Amgen, ARIAD, Astex, Bristol-Myers Squibb, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr de Lavallade has disclosed that he has received payment for speaking and teaching from Bristol-Myers Squibb and Incyte. He has also disclosed membership on an advisory committee or a review panel for Incyte. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Martinelli has disclosed that he has received consulting fees from Ariad/Incyte, Amgen, Celgene, J&J, Pfizer, and Roche. He also received fees for non-CME services received directly from commercial interest or their agents from Abbvie, Bristol-Myers Squibb, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.